Posted in | News | Gold | Mining Business

Midas Gold and Franco-Nevada Complete Golden Meadows Project Transaction

Midas Gold Corp. ("Midas Gold" or "Corporation") today announced that it and its subsidiaries (the "Midas Group") have completed the previously announced US$15.0 million transaction with Franco-Nevada Corporation ("Franco-Nevada") and one of its subsidiaries whereby the Midas Group has sold certain rights to a royalty on future gold production from the Golden Meadows Project in Valley County, Idaho as well as two million warrants exercisable for shares of Midas Gold.

"We are pleased to have completed the US$15 million transactions with Franco-Nevada and its subsidiary," said Stephen Quin, President & CEO of Midas Gold. "These funds allow us to continue advancing the evaluation of the world-class Golden Meadows gold-silver-antimony-tungsten project in Idaho. The Golden Meadows project benefits from a large, high-grade mineral resource located in a low-risk jurisdiction that has the potential to support a long-life, low-cost, open pit mining operation with significant production as demonstrated in the Preliminary Economic Assessment published in September 2012. The mineral resources and potential future development area are contained within a brownfields site that has been extensively mined for almost 100 years, and offers the potential for reclamation and restoration of past disturbance contemporaneously with development of a new mine, designed to modern standards, that results in an enhanced environmental outcome as compared to the current situation."

Additional details of the transactions can be found in Midas Gold's news release dated May 7, 2013.

Advisors
Haywood Securities Inc. acted as financial advisor to Midas Gold and its board of directors in respect of this transaction.

Majority Voting Policy
The board of directors of Midas Gold (the "Board") has adopted a majority voting policy which requires, in an uncontested election of directors, that any nominee in respect of whom a greater number of votes "withheld" than votes "for" are validly cast will promptly submit his or her offer of resignation for the consideration of Midas Gold's Corporate Governance Committee. The committee will make a recommendation to the Board after reviewing the matter as to whether to accept or reject the resignation. In considering the resignation offer, the committee and the Board will consider all factors they deem relevant, and the Board's decision as to accept or reject the resignation offer will be disclosed to the public. A director who offers his or her resignation pursuant to the policy will not participate in any meeting of the Board or the committee at which the resignation offer is considered. The policy would not apply in circumstances involving contested director elections.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Franco-Nevada Corporation. (2019, February 17). Midas Gold and Franco-Nevada Complete Golden Meadows Project Transaction. AZoMining. Retrieved on November 21, 2024 from https://www.azomining.com/News.aspx?newsID=8163.

  • MLA

    Franco-Nevada Corporation. "Midas Gold and Franco-Nevada Complete Golden Meadows Project Transaction". AZoMining. 21 November 2024. <https://www.azomining.com/News.aspx?newsID=8163>.

  • Chicago

    Franco-Nevada Corporation. "Midas Gold and Franco-Nevada Complete Golden Meadows Project Transaction". AZoMining. https://www.azomining.com/News.aspx?newsID=8163. (accessed November 21, 2024).

  • Harvard

    Franco-Nevada Corporation. 2019. Midas Gold and Franco-Nevada Complete Golden Meadows Project Transaction. AZoMining, viewed 21 November 2024, https://www.azomining.com/News.aspx?newsID=8163.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.